Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
Dovato (dolutegravir/lamivudine) is the second approved two-antiretroviral regimen.
Timothy Brown may have company after a man’s virus went into remission following an HIV-resistant stem cell transplant to treat his cancer.
Previous studies found Tivicay monotherapy was subpar, but this trial switched people to the drug who had started combo treatment early.
More high-quality evidence is needed to determine how this class of HIV medications may affect weight gain.
So argued researchers behind a study that switched people from triple-antiretroviral regimens to Tivicay monotherapy.
Researchers presented 100-week data on a trial of the antiretroviral (ARV) regimen at the international AIDS conference.
A large ongoing study in Botswana has found that about 1 in 150 babies exposed to Tivicay at conception developed such birth defects.
Tivicay (dolutegravir) is a next-generation integrase inhibitor.
The integrase inhibitor is included in the single-tablet HIV regimens Triumeq and Juluca.
After a gay man tested HIV positive, a test of his hair indicated he’d adhered well to PrEP—but did he contract a drug-resistant strain?
Juluca is a single-tablet regimen for HIV.
ViiV alleges that the bictegravir component of the tablet infringes on its own patent for Tivicay (dolutegravir).
The single-tablet regimen contains ViiV’s integrase inhibitor dolutegravir and Janssen’s NNRTI rilpivirine.
The combo of Tivicay (dolutegravir) and Edurant (rilpivirine) showed comparable efficacy to three- and four-drug regimens in major trials.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.